Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Deferred Revenue (2022 - 2025)

Atara Biotherapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $716000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 99.25% year-over-year to $716000.0; the TTM value through Dec 2025 reached $716000.0, down 99.25%, while the annual FY2025 figure was $716000.0, 99.25% down from the prior year.
  • Current Deferred Revenue reached $716000.0 in Q4 2025 per ATRA's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $123.2 million in Q1 2024 to a low of $716000.0 in Q4 2025.
  • Average Current Deferred Revenue over 4 years is $39.8 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: soared 1140.97% in 2024, then tumbled 99.25% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $8.0 million in 2022, then soared by 872.91% to $77.8 million in 2023, then grew by 22.17% to $95.1 million in 2024, then crashed by 99.25% to $716000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Current Deferred Revenue are $716000.0 (Q4 2025), $1.0 million (Q3 2025), and $1.6 million (Q2 2025).